DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bimatoprost/Timolol Versus Travoprost/Timolol

Information source: Kasr El Aini Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Glaucoma

Intervention: Ganfort (Drug); Duotrav (Drug)

Phase: N/A

Status: Completed

Sponsored by: Kasr El Aini Hospital

Official(s) and/or principal investigator(s):
Tamer A Macky, MD FRCS, Principal Investigator, Affiliation: Cairo University


The purpose of this study is to compare 2 fixed combination medications in intraocular pressure lowering.

Clinical Details

Official title: Bimatoprost/Timolol Versus Travoprost/Timolol Fixed Combinations in an Egyptian Population: A Hospital-Based Prospective Randomized Study

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Percentage of drop of intraocular pressures from baseline.

Detailed description: PURPOSE: To compare the efficacy of bimatoprost/timolol (BTFC) or travoprost/timolol (TTFC) fixed combinations on intraocular pressure (IOP) reduction in an Egyptian population. METHODS: Patients with primary open angle glaucoma (POAG) were randomized to receive either BTFC or TTFC. IOPs were measured at baseline, 2 weeks, and 1, 2, 4, and 6 months. The primary outcome measures were the mean change in IOP from baseline


Minimum age: N/A. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Glaucoma

Exclusion Criteria:

- No other ocular diseases

Locations and Contacts

Kasr El Aini Hospital, Cairo, Egypt
Additional Information

Starting date: January 2011
Last updated: March 1, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017